Delta-like protein 3 expression and therapeutic targeting in neuroendocrine prostate cancer

DLL3 is overexpressed in neuroendocrine prostate cancer and is a potential therapeutic target. Lessons from one tumor help with another Neuroendocrine prostate cancer is an aggressive tumor subtype that can arise late in the course of the disease and drive therapeutic resistance. Puca et al. demonstrate the feasibility of targeting it with an antibody-drug conjugate against delta-like protein 3 (DLL3), a recently identified therapeutic being tested in small cell lung cancer, another aggressive neuroendocrine tumor. The authors confirmed the presence of DLL3 in most neuroendocrine prostate cancers, but not in localized tumors or normal prostate, and showed its association with aggressive clinical features. They then demonstrated the effectiveness of targeting DLL3 in multiple mouse models as well as a human patient. Histologic transformation to small cell neuroendocrine prostate cancer occurs in a subset of patients with advanced prostate cancer as a mechanism of treatment resistance. Rovalpituzumab tesirine (SC16LD6.5) is an antibody-drug conjugate that targets delta-like protein 3 (DLL3) and was initially developed for small cell lung cancer. We found that DLL3 is expressed in most of the castration-resistant neuroendocrine prostate cancer (CRPC-NE) (36 of 47, 76.6%) and in a subset of castration-resistant prostate adenocarcinomas (7 of 56, 12.5%). It shows minimal to no expression in localized prostate cancer (1 of 194) and benign prostate (0 of 103). DLL3 expression correlates with neuroendocrine marker expression, RB1 loss, and aggressive clinical features. DLL3 in circulating tumor cells was concordant with matched metastatic biopsy (87%). Treatment of DLL3-expressing prostate cancer xenografts with a single dose of SC16LD6.5 resulted in complete and durable responses, whereas DLL3-negative models were insensitive. We highlight a patient with neuroendocrine prostate cancer with a meaningful clinical and radiologic response to SC16LD6.5 when treated on a phase 1 trial. Overall, our findings indicate that DLL3 is preferentially expressed in CRPC-NE and provide rationale for targeting DLL3 in patients with DLL3-positive metastatic prostate cancer.

[1]  J. Hartley,et al.  Pre-clinical pharmacology and mechanism of action of SG3199, the pyrrolobenzodiazepine (PBD) dimer warhead component of antibody-drug conjugate (ADC) payload tesirine , 2018, Scientific Reports.

[2]  Joshua M. Stuart,et al.  Clinical and Genomic Characterization of Treatment-Emergent Small-Cell Neuroendocrine Prostate Cancer: A Multi-institutional Prospective Study. , 2018, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[3]  D. Lorente,et al.  Circulating tumour cell increase as a biomarker of disease progression in metastatic castration-resistant prostate cancer patients with low baseline CTC counts , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[4]  Dong Gao,et al.  Patient derived organoids to model rare prostate cancer phenotypes , 2018, Nature Communications.

[5]  Jason S. Lewis,et al.  Fc-Mediated Anomalous Biodistribution of Therapeutic Antibodies in Immunodeficient Mouse Models. , 2018, Cancer research.

[6]  David S. K. Lu,et al.  Phenotypic Heterogeneity of Circulating Tumor Cells Informs Clinical Decisions between AR Signaling Inhibitors and Taxanes in Metastatic Prostate Cancer. , 2017, Cancer research.

[7]  Michael D. Nyquist,et al.  Androgen Receptor Pathway-Independent Prostate Cancer Is Sustained through FGF Signaling. , 2017, Cancer cell.

[8]  Anne-Katrin Emde,et al.  Next-Generation Rapid Autopsies Enable Tumor Evolution Tracking and Generation of Preclinical Models. , 2017, JCO precision oncology.

[9]  J. McKenney,et al.  Prognostic value of DLL3 expression and clinicopathologic features in small cell bladder cancer (SCBC). , 2017 .

[10]  Henry W. Long,et al.  Rb1 and Trp53 cooperate to suppress prostate cancer lineage plasticity, metastasis, and antiandrogen resistance , 2017, Science.

[11]  M. Rubin,et al.  SOX2 promotes lineage plasticity and antiandrogen resistance in TP53- and RB1-deficient prostate cancer , 2017, Science.

[12]  Luc Girard,et al.  ASCL1 and NEUROD1 Reveal Heterogeneity in Pulmonary Neuroendocrine Tumors and Regulate Distinct Genetic Programs. , 2016, Cell reports.

[13]  X. Zhang,et al.  Notch promotes tumor metastasis in a prostate-specific Pten-null mouse model. , 2016, The Journal of clinical investigation.

[14]  Matteo Benelli,et al.  Divergent clonal evolution of castration resistant neuroendocrine prostate cancer , 2016, Nature Medicine.

[15]  H. Beltran,et al.  The Initial Detection and Partial Characterization of Circulating Tumor Cells in Neuroendocrine Prostate Cancer , 2015, Clinical Cancer Research.

[16]  T. Buhl,et al.  NOTCH, ASCL1, p53 and RB alterations define an alternative pathway driving neuroendocrine and small cell lung carcinomas , 2015, International journal of cancer.

[17]  C. Rudin,et al.  A DLL3-targeted antibody-drug conjugate eradicates high-grade pulmonary neuroendocrine tumor-initiating cells in vivo , 2015, Science Translational Medicine.

[18]  Martin Vingron,et al.  Comprehensive genomic profiles of small cell lung cancer , 2015, Nature.

[19]  Lawrence D. True,et al.  Integrative Clinical Genomics of Advanced Prostate Cancer , 2015, Cell.

[20]  M. Landers,et al.  Analytical Validation and Capabilities of the Epic CTC Platform: Enrichment-Free Circulating Tumour Cell Detection and Characterization , 2015, Journal of circulating biomarkers.

[21]  W. Huber,et al.  Moderated estimation of fold change and dispersion for RNA-seq data with DESeq2 , 2014, Genome Biology.

[22]  Tao Wang,et al.  ASCL1 is a lineage oncogene providing therapeutic targets for high-grade neuroendocrine lung cancers , 2014, Proceedings of the National Academy of Sciences.

[23]  Paul Theodor Pyl,et al.  HTSeq—a Python framework to work with high-throughput sequencing data , 2014, bioRxiv.

[24]  M. Rubin,et al.  Proposed Morphologic Classification of Prostate Cancer With Neuroendocrine Differentiation , 2014, The American journal of surgical pathology.

[25]  M. Rubin,et al.  High fidelity patient-derived xenografts for accelerating prostate cancer discovery and drug development. , 2014, Cancer research.

[26]  K. Kaestner,et al.  Mash1 expression is induced in neuroendocrine prostate cancer upon the loss of Foxa2 , 2013, The Prostate.

[27]  Francine E. Garrett-Bakelman,et al.  Base-Pair Resolution DNA Methylation Sequencing Reveals Profoundly Divergent Epigenetic Landscapes in Acute Myeloid Leukemia , 2012, PLoS genetics.

[28]  Benjamin E. Gross,et al.  The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. , 2012, Cancer discovery.

[29]  David R. Kelley,et al.  Differential gene and transcript expression analysis of RNA-seq experiments with TopHat and Cufflinks , 2012, Nature Protocols.

[30]  M. Gerstein,et al.  Molecular characterization of neuroendocrine prostate cancer and identification of new drug targets. , 2011, Cancer discovery.

[31]  Felix Krueger,et al.  Bismark: a flexible aligner and methylation caller for Bisulfite-Seq applications , 2011, Bioinform..

[32]  M. Walker,et al.  Repression of Androgen Receptor Activity by HEYL, a Third Member of the Hairy/Enhancer-of-split-related Family of Notch Effectors* , 2011, The Journal of Biological Chemistry.

[33]  E. Kremmer,et al.  Notch inhibition by the ligand DELTA-LIKE 3 defines the mechanism of abnormal vertebral segmentation in spondylocostal dysostosis. , 2011, Human molecular genetics.

[34]  Hervé Rouault,et al.  Mechanism and Significance of cis-Inhibition in Notch Signalling , 2011, Current Biology.

[35]  Zhijun Tang,et al.  Notch signaling is required for normal prostatic epithelial cell proliferation and differentiation. , 2006, Developmental biology.

[36]  Y. Yatabe,et al.  ASH1 gene is a specific therapeutic target for lung cancers with neuroendocrine features. , 2005, Cancer research.

[37]  J. Boulter,et al.  The divergent DSL ligand Dll3 does not activate Notch signaling but cell autonomously attenuates signaling induced by other DSL ligands , 2005, The Journal of cell biology.

[38]  M. Walker,et al.  Hey1, a Mediator of Notch Signaling, Is an Androgen Receptor Corepressor , 2005, Molecular and Cellular Biology.

[39]  S. Varambally,et al.  JAGGED1 Expression Is Associated with Prostate Cancer Metastasis and Recurrence , 2004, Cancer Research.

[40]  Chan Zeng,et al.  Epidermal growth factor receptor in non-small-cell lung carcinomas: correlation between gene copy number and protein expression and impact on prognosis. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[41]  R. Beddington,et al.  Axial skeletal defects caused by mutation in the spondylocostal dysplasia/pudgy gene Dll3 are associated with disruption of the segmentation clock within the presomitic mesoderm. , 2002, Development.

[42]  M. Rubin,et al.  Neuroendocrine expression in metastatic prostate cancer: evaluation of high throughput tissue microarrays to detect heterogeneous protein expression. , 2000, Human pathology.

[43]  C. Rudin,et al.  Rovalpituzumab tesirine, a DLL3-targeted antibody-drug conjugate, in recurrent small-cell lung cancer: a first-in-human, first-in-class, open-label, phase 1 study. , 2017, The Lancet. Oncology.

[44]  Thomas R. Gingeras,et al.  STAR: ultrafast universal RNA-seq aligner , 2013, Bioinform..